US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Investing.com -- Lineage Cell Therapeutics Inc (NYSE American:NYSE:LCTX) stock rose 2.7% after the company announced positive 36-month results from a Phase 1/2a clinical study of its RG6501 (OpRegen) cell therapy for geographic atrophy secondary to age-related macular degeneration.
The data, presented at Clinical Trials at the Summit 2025, showed that patients who received OpRegen maintained improvements in vision and retinal structure for at least three years following a single administration. Patients in Cohort 4, who had less advanced disease, demonstrated a mean improvement of 6.2 letters in Best Corrected Visual Acuity (BCVA) at the 36-month mark, compared to 5.5 letters at 24 months.
Results were particularly promising in the five patients who received extensive OpRegen coverage across their geographic atrophy areas, with these patients showing a mean BCVA improvement of 9.0 letters at 36 months, up from 7.4 letters at 24 months.
"Long term clinical outcomes following a single administration of OpRegen cell therapy is challenging the long-held view that GA causes irreversible damage," stated Brian M. Culley, Lineage CEO. "Among patients who received fulsome coverage by OpRegen cell therapy, anatomical and functional benefits from a single administration have lasted for at least three years."
The therapy also demonstrated sustained improvements in retinal structure through 36 months, with treated eyes maintaining improvements in the retinal pigment epithelium drusen complex area (+1.9 mm²) while untreated fellow eyes showed deterioration (-3.8 mm²).
RG6501 is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech. The therapy is currently being evaluated in a Phase 2a "GAlette study" that is testing proprietary surgical devices for improved subretinal delivery of the cell therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.